Research
Tesamorelin
A stabilised analogue of growth hormone-releasing hormone, carrying a trans-3-hexenoyl group that slows its breakdown.
Available in the catalogue
Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.
What is being investigated
Directions the published work points at, and how far each has actually got. These are open questions, not established effects: most of what looks promising in cells does not replicate in animals, and most of what works in animals does not work in people. Nothing here is a claim about what this compound does for anyone.
- Visceral fat in HIV-associated lipodystrophy
The indication its randomised programme was actually run in, over 26 weeks against placebo in more than four hundred participants, with visceral adipose tissue measured directly rather than inferred.
Human trials
- Liver fat
Later randomised work asked whether the same reduction extends to fat in the liver in people with HIV and hepatic steatosis.
Human trials
- Cognition in older adults
A randomised trial used this compound to ask whether raising growth hormone and IGF-1 affects cognitive test scores in older adults, including those with mild cognitive impairment. A single trial in a field where single trials frequently do not replicate.
Human trials
Published research
Every reference below was checked against the published record before being listed, with the model each study used.
- Falutz et al. (2007)New England Journal of Medicine
Reported reduction in visceral adipose tissue over 26 weeks against placebo, with IGF-1 elevation, in 412 participants.
human, randomised double-blind placebo-controlled Source
- Falutz et al. (2010)Journal of Clinical Endocrinology & Metabolism
Pooled efficacy and safety analysis across two multicentre double-blind placebo-controlled trials, with safety extension data.
human, pooled analysis of two phase 3 trials Source
Further reading
Longer articles on handling, analysis and what the published work reports.
- Tesamorelin (Egrifta): what the research says
An approved medicine in the US with one of the largest trial programmes here. Every efficacy trial was in HIV-associated visceral fat, and that limits it.
- How to store research peptides
Lyophilised peptides at -20°C, reconstituted at 2–8°C, ambient in transit. Why the dry cake tolerates shipping, and what actually degrades a vial.
- Peptide shelf life and stability
How long lyophilised and reconstituted peptides keep, and the four things that shorten it: temperature, moisture, light and oxidation. Storage figures included.
- How to reconstitute lyophilised peptides
How to reconstitute a lyophilised peptide with bacteriostatic water without damaging it: why you run the liquid down the vial wall and never shake it.